Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The project is a randomized clinical trial with a follow up time of 12 months comparing the effects of surgical treatment of idiopathic macular holes. Patients are randomized to vitrectomy alone, vitrectomy plus ICG-assisted ILM peeling or vitrectomy plus Trypanblue-assisted ILM peeling. At baseline patients are characterized using ETDRS visual charts, tests of aniseikonia, OCT3, autoperimetri and fundus photography. Per- and postoperative complications are registered.
Data analyses will help clarify the effect of ILM peeling on hole closure and visual acuity. Comparing results after ICG- and Trypanblue-assisted ILM peeling will help clarify the topic of a toxic effect on retinal cells after staining and peeling of the ILM. Changes in intraretinal morphology before and after dye-assisted ILM peeling will be studied using OCT3 imaging and the patients' subjective opinion on the surgical results will be analyzed using quality of life questionnaires and metamorphopsia tests.
| Condition | Intervention |
|---|---|
|
Idiopathic Macular Hole Stage 2 and 3 |
Procedure: Vitrectomy without ILM peeling Procedure: Vitrectomy with ICG-assisted ILM peeling Procedure: Vitrectomy with Trypanblue assisted ILM peeling |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Randomised Clinical Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes |
- Visual Acuity
- Anatomic Success
- Visual field defects
- Metamorphopsia
- Retinal Pigmentepitelium Atrophy
- Intraretinal Morphological Changes
- Quality of Life
| Estimated Enrollment: | 80 |
| Study Start Date: | August 2005 |
| Estimated Study Completion Date: | January 2008 |
Eligibility| Genders Eligible for Study: | Both |
Inclusion Criteria:
- Idiopathic macular hele stage 2 or 3.
- Duration of Symptoms ≤ 12 months.
- Visual acuity ≥ 34 ETDRS letters.
- Intraocular pressure ≤ 23 mmHg.
- Informed consent.
Exclusion Criteria:
- Previous macular hole in project eye
- Macular pucker worse than a cellophane macular reflex.
- Previous surgery or disease in the eye affecting retinal function.
- Systemic disease affection vision including diabetes mellitus with level of retinopathy ≥ 14a.
- Amblyopia i project eye.
Contacts and Locations| Denmark | |
| Department of Ophthalmology, Glostrup Hospital | |
| Copenhagen, Denmark, DK-2600 | |
| Study Director: | Morten la Cour, MD,DMSc,EBOD | Glostrup Hospital, Department of Ophthalmology |
| Study Director: | Michael Larsen, MD, DMSc | Glostrup Hospital, Department of Ophthalmology |
More Information
No publications provided by Glostrup University Hospital, Copenhagen
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00302328 History of Changes |
| Other Study ID Numbers: | COMAH |
| Study First Received: | March 13, 2006 |
| Last Updated: | September 3, 2009 |
| Health Authority: | Denmark: The Danish National Committee on Biomedical Research Ethics |
Additional relevant MeSH terms:
|
Retinal Perforations Retinal Diseases Eye Diseases |
ClinicalTrials.gov processed this record on May 19, 2013